COEP
Coeptis Therapeutics·NASDAQ
--
--(--)
--
--(--)
7.46 / 10
Outperform
Capital flow evaluation is positive with a score of 7.46/10, reflecting robust fund inflows. However, the overall fund flow trend is negative, suggesting short-term volatility. There is no analyst coverage data available, so the analysis is primarily based on fund flow patterns. The sentiment score of 7.46 aligns with the fund flow strength, but the absence of analyst ratings limits the depth of the assessment.
Fund Flow Rating
Is money flowing into or out of COEP?
- COEP holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.46/10 (Outperform).
